| Applications of machine learning in drug discovery and development | Nature Reviews Drug Discovery | 2019 | 558 |
| Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation | New England Journal of Medicine | 2019 | 538 |
| The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis | Journal of Hepatology | 2019 | 518 |
| Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial | Lancet Oncology, The | 2019 | 344 |
| Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial | Lancet Oncology, The | 2019 | 343 |
| First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers | Journal of Clinical Oncology | 2019 | 274 |
| Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial | Lancet, The | 2019 | 227 |
| Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non-Small Cell Lung Cancer Treated With Nivolumab | JAMA Oncology | 2019 | 216 |
| Cooperation between Constitutive and Inducible Chemokines Enables T Cell Engraftment and Immune Attack in Solid Tumors | Cancer Cell | 2019 | 213 |
| Nivolumab for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Patients Ineligible for or Having Failed Autologous Transplantation: A Single-Arm, Phase II Study | Journal of Clinical Oncology | 2019 | 173 |
| Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy: Three-Year Follow-up of a Randomized Phase 3 Trial | JAMA Oncology | 2019 | 173 |
| Third-Line Nivolumab Monotherapy in Recurrent SCLC: CheckMate 032 | Journal of Thoracic Oncology | 2019 | 163 |
| Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis | Lancet Oncology, The | 2019 | 149 |
| Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical Trial | Journal of Thoracic Oncology | 2019 | 141 |
| Hindered dialkyl ether synthesis with electrogenerated carbocations | Nature | 2019 | 136 |
| Nivolumab (NIVO) + ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Results from CheckMate 040. | Journal of Clinical Oncology | 2019 | 136 |
| Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 Trial | Journal of Clinical Oncology | 2019 | 135 |
| The Evolution of High-Throughput Experimentation in Pharmaceutical Development and Perspectives on the Future | Organic Process Research and Development | 2019 | 128 |
| Safety and Efficacy of Nivolumab Monotherapy in Recurrent or Metastatic Cervical, Vaginal, or Vulvar Carcinoma: Results From the Phase I/II CheckMate 358 Trial | Journal of Clinical Oncology | 2019 | 127 |
| Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial | Lancet Oncology, The | 2019 | 122 |
| Pegbelfermin (BMS-986036), PEGylated FGF21, in Patients with Obesity and Type 2 Diabetes: Results from a Randomized Phase 2 Study | Obesity | 2019 | 109 |
| Nivolumab Alone and With Ipilimumab in Previously Treated Metastatic Urothelial Carcinoma: CheckMate 032 Nivolumab 1 mg/kg Plus Ipilimumab 3 mg/kg Expansion Cohort Results | Journal of Clinical Oncology | 2019 | 108 |
| Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis | Journal of Hepatology | 2019 | 106 |
| Structure, heterogeneity and developability assessment of therapeutic antibodies | MAbs | 2019 | 103 |
| Blood-brain barrier permeable nano immunoconjugates induce local immune responses for glioma therapy | Nature Communications | 2019 | 101 |
